SynthesisWorld journal of surgical oncology2026
Efficacy of endocrine therapy alone versus endocrine therapy combined with radiotherapy after breast-conserving surgery in older patients with early-stage estrogen receptor-positive breast cancer: a meta-analysis.
Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the general adult female population, the benefit of adjuvant radiotherapy following breast-conserving surgery (BCS) is well established. Nevertheless, whether radiotherapy should be routinely added after BCS for older women with estrogen receptor-positive (ER+) breast cancer remains controversial. The present meta-analysis aimed to evaluate the efficacy and clinical value of endocrine therapy (ET) plus radiotherapy relative to ET alone in this population.
methodsA systematic search was conducted across the Cochrane Library, PubMed, Embase, and Web of Science. Studies comparing ET plus radiotherapy versus ET alone in older (≥ 60 years) women with ER+ breast cancer after BCS were eligible. The primary conclusions were drawn exclusively on randomized controlled trials (RCTs), with findings from cohort studies serving as supporting evidence. Methodological quality was evaluated utilizing the National Institutes of Health Quality Assessment Tools. The meta-analysis was conducted in STATA (v15.0). Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were computed. Appropriate models were chosen for pooling results depending on between-study heterogeneity. Leave-one-out sensitivity analyses were performed to evaluate the robustness of findings. Outcomes comprised breast cancer-specific survival (BCSS), overall survival (OS), distant metastasis rate (DMR), local recurrence rate (LRR), and 5-year disease-free survival (DFS). Subgroup analyses were conducted by age, geographic region, ET regimen, radiotherapy regimen, and nodal status. For LRR, the absolute risk reduction (ARR) and number needed to treat (NNT) were calculated.
resultsTwenty studies (9 RCTs, 11 cohort studies) met the eligibility criteria. The primary analysis based on RCTs revealed that radiotherapy plus ET reduced the risk of local recurrence (HR = 0.33, 95% CI: 0.18-0.60); the corresponding ARR was 3.2%, and NNT was 31. No statistically significant differences were observed between the two groups in OS (HR = 1.00, 95% CI: 0.89-1.13), BCSS (HR = 0.96, 95% CI: 0.48-1.93), DMR (HR = 1.12, 95% CI: 0.67-1.87), or 5-year DFS (HR = 0.64, 95% CI: 0.35-1.16). The results from cohort studies were reported separately as supporting evidence.
conclusionFor older women with early-stage ER+ breast cancer after BCS, adjuvant radiotherapy combined with ET reduces the risk of local recurrence, yet this combination demonstrates no statistically significant improvement in OS, BCSS, DMR, or 5-year DFS. The absolute benefit of radiotherapy is modest. Treatment decisions should involve individualized trade-offs incorporating the risk of recurrence, burden of comorbidities, life expectancy, and patient preferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.